Article Text

Download PDFPDF
MHRA issues further update on fluoroquinolone safety

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Key learning points

  • The Medicines and Healthcare products Regulatory Agency (MHRA) has issued another safety update on fluoroquinolone antibiotics.

  • Fluoroquinolones must now only be used when other antibiotics are inappropriate.

  • Patients should be advised to stop taking a fluoroquinolone antibiotic at the first sign of a serious adverse reaction.

The licensed indications for all systemic fluoroquinolones have been updated to restrict their use to situations in which other commonly recommended antibiotics are inappropriate.1

Overview

In August and September 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued two safety updates on the use of fluoroquinolone antibiotics.1–3 The first update reminded healthcare professionals that systemic fluoroquinolone antibiotics are associated with a risk of …

View Full Text

Footnotes

  • Provenance and peer review Commissioned; internally peer reviewed.